LIM-1215 Xenograft Model Service for Colon Cancer

The LIM-1215 xenograft model represents a well-characterized preclinical platform for colon cancer research, offering robust tumorigenicity and defined molecular features that enable precise evaluation of therapeutic strategies. Alfa Cytology delivers comprehensive LIM-1215 xenograft model services, leveraging validated protocols and stringent quality control to support your preclinical colon cancer research programs with reliable, reproducible data.

Overview of LIM-1215 Xenograft Model for Colon Cancer

LIM-1215 is a human colorectal carcinoma cell line originally established from a patient with hereditary nonpolyposis colorectal cancer (HNPCC). The cell line exhibits epithelial morphology, pseudodiploid karyotype with a modal chromosome number of 46, and carries a distinctive 13p+ marker chromosome. Molecular characterization reveals a stabilizing beta-catenin mutation and elevated EphA1 receptor expression, both implicated in colorectal tumorigenesis. The cells express tumor-associated glycoproteins including cadherin-17 and EpCAM, and demonstrate tumorigenic potential with confirmed xenograft formation in immunocompromised mice.

In xenograft applications, LIM-1215 demonstrates robust tumor take rates and progressive growth dynamics, making it suitable for evaluating anti-EGFR therapies, combination regimens, and novel targeted agents. The model has been extensively utilized in studies assessing cetuximab resistance mechanisms, somatostatin analog antitumor effects, and triple monoclonal antibody inhibition strategies. Its well-defined molecular landscape and validated in vivo behavior position LIM-1215 as a reliable tool for preclinical colon cancer drug development.

Figure 1. Dose response curves obtained from combination of Cs with Cur. 2a: HT-29 cell line; 2b: Caco-2 cell line; 2c: LIM-1215 cell line; 2d: LIM-2405 cell line. (Bali, Hana, et al., 2020)

Cell Line Information: LIM-1215

The following table summarizes key characteristics of the LIM-1215 cell line relevant to xenograft model development:

Our Services

Alfa Cytology provides end-to-end LIM-1215 xenograft model services tailored to your preclinical research objectives. Our experienced team manages every phase from cell line authentication and expansion to in vivo execution and comprehensive endpoint analysis, ensuring consistent, high-quality data delivery for your colon cancer therapeutic programs. We maintain rigorous quality standards and flexible study designs to accommodate diverse pharmacological and translational research needs.

Workflow of LIM-1215 Xenograft Model Construction

The construction of LIM-1215 xenograft models follows a standardized, multi-step workflow designed to ensure reproducible tumor growth and reliable pharmacological readouts. Each stage incorporates stringent quality control measures to maintain model integrity throughout the study duration.

1. Cell Expansion and Authentication: LIM-1215 cells are expanded under optimized culture conditions and authenticated via STR profiling to confirm identity prior to inoculation.
2. Quality Control Screening: Expanded cell banks undergo mycoplasma testing, viability assessment, and morphological verification to ensure batch consistency.
3. Cell Preparation for Injection: Cells are harvested at logarithmic growth phase, washed, resuspended in serum-free medium with Matrigel, and kept on ice until injection.
4. Animal Preparation and Acclimation: Immunodeficient mice (typically NOD/SCID or nude strains) are acclimated for one week and randomized into treatment groups based on body weight.
5. Subcutaneous Tumor Inoculation: LIM-1215 cells are injected subcutaneously into the right flank at defined concentrations (typically 1-5 x 10^6 cells per mouse) under sterile conditions.
6. Tumor Monitoring and Caliper Measurement: Tumor dimensions are measured twice weekly using digital calipers; volume is calculated via the modified ellipsoid formula (length x width^2 / 2).
7. Endpoint Analysis and Tissue Collection: At study termination, tumors are excised, weighed, and processed for histopathology, biomarker analysis, or downstream molecular profiling as specified.

Figure 2: Schematic workflow illustrating the derivation and construction of the LIM-1215 Xenograft Model at Alfa Cytology.

Case Study-LIM-1215 Xenograft Model Development

Our internal validation studies with the LIM-1215 xenograft model have demonstrated consistent tumor take rates and predictable growth kinetics across multiple independent experiments. Preliminary data indicate robust response to standard-of-care reference compounds, with tumor growth inhibition metrics aligning with published literature values. Detailed efficacy datasets, pharmacokinetic correlations, and histopathological characterization reports are available upon formal inquiry. Please contact our scientific team to discuss specific data packages and customized study parameters.

Why Choose Alfa Cytology?

Alfa Cytology combines scientific expertise with operational excellence to deliver LIM-1215 xenograft models that meet the highest standards of preclinical research. Our integrated service platform ensures seamless execution from study design to data delivery.

• Validated cell line authentication and mycoplasma-free guarantees for every study batch.
• Standardized xenograft protocols with documented tumor take rates and growth curves for LIM-1215.
• Flexible study designs accommodating single-agent, combination, and dose-escalation paradigms.
• Comprehensive endpoint analysis including tumor biometrics, histopathology, and biomarker profiling.
• Dedicated project management ensuring transparent communication and timely milestone delivery.
• Competitive timelines and cost-efficient pricing without compromising data quality or animal welfare standards.

Contact Us

Ready to advance your colon cancer preclinical research with our LIM-1215 xenograft model services? Contact us today to discuss your study requirements, review available data packages, and receive a customized proposal. Reach out to our scientific team and let Alfa Cytology support your next therapeutic development milestone.

For research use only. Not intended for any clinical use.